Postmenopausal Osteoporosis Treatment Market Analysis, Trends, & Forecast 2032

1
Postmenopausal Osteoporosis Treatment Market
Opportunity, Demand, recent trends, Major Driving
Factors and Business Growth Strategies 2032
2

• Industry Insights

• Postmenopausal Osteoporosis Treatment Market size
  is estimated to depict 4.6 CAGR from 2023 to
  2032 attributed to the surge in supportive
  government initiatives and healthcare policies
  worldwide.
• The influx of subsidized healthcare services,
  medication affordability, and supportive RD
  initiatives are creating an environment conducive
  to effective osteoporosis management.
• Additionally, there has been significant increase
  in government-driven regulations and guidelines
  for ensuring quality standards and patient safety
  while promoting the integration of innovative
  treatment approaches.
• Furthermore, the rising efforts by industry
  players on strengthening their market position
  through the development of advanced generic
  formulations and device engineering to enhance
  patient access to crucial treatment options will
  augment the industry outlook.

3

• For instance, in November 2023, Teva
  Pharmaceuticals Inc., a U.S. subsidiary of Teva
  Pharmaceutical Industries Ltd. received approval
  to market the generic version of Forteo1, an
  injectable containing teriparatide, prescribed to
  treat osteoporosis in certain male and female
  patients.
• Based on drug type, the market share from the
  hormone replacement therapy (HRT) segment is
  anticipated to gain 4.8 CAGR between 2023 and
  2032.
• HRT has emerged as an effective treatment
  approach for postmenopausal osteoporosis as it
  helps to maintain bone density, reduce fracture
  risk, and manage symptoms.
• Additionally, the increasing adoption of hormone
  replacement therapies to treat postmenopausal
  women coupled with the ongoing RD efforts for
  formulations will propel the segment expansion.

4

• Regional Analysis

• Regionally, the Asia Pacific postmenopausal
  osteoporosis treatment market is set to exhibit
  5.2 growth rate through 2032 driven by the aging
  population and increasing awareness of
  osteoporosis management.

• Competitive Analysis

• Amgen Inc.
• Theramex (PAI and Carlyle)
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Novartis AG
• Mylan Inc. (Viatris)

5
Postmenopausal Osteoporosis Treatment Market _at_
https//www.gminsights.com/industry-analysis/postm
enopausal-osteoporosis-treatment-market
Request for sample of this research report _at_
https//www.gminsights.com/request-sample/detail/7
186
Request for customization _at_ https//www.gminsights
.com/roc/7186
6
Stay In Touch Social Media
7
THANK YOU
www.gminsights.com